Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Ophthalmology"
DOI: 10.1007/s10384-018-0562-0
Abstract: PurposeTo evaluate the efficacy of intravitreal aflibercept therapy using a treat-and-extend regimen on treatment-naïve pachychoroid neovasculopathy (PNV) and Type 1 neovascular age-related macular degeneration (AMD).MethodsWe retrospectively studied 42 eyes with PNV and 60 eyes with… read more here.
Keywords: pachychoroid neovasculopathy; extend regimen; polypoidal lesions; type neovascular ... See more keywords
A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study)
Sign Up to like & getrecommendations! Published in 2020 at "Eye"
DOI: 10.1038/s41433-020-0901-5
Abstract: Purpose To evaluate the efficacy of intravitreal aflibercept as a second-line therapy in eyes with persistent diabetic macular oedema (DMO) despite receiving initial bevacizumab treatment. Methods A prospective multicentre study was conducted in nine academic… read more here.
Keywords: treatment; study; extend regimen; intravitreal aflibercept ... See more keywords
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-76354-1
Abstract: The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective… read more here.
Keywords: year; extend regimen; intravitreal aflibercept; treat extend ... See more keywords
EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Retina"
DOI: 10.1097/iae.0000000000002582
Abstract: PURPOSE To evaluate 52-week efficacy and safety of a treat-and-extend regimen of intravitreal aflibercept 2 mg on treatment-naive Type 3 neovascularization lesions. METHODS Phase IV, prospective, open-label, single-arm, multicenter trial including patients with untreated Stage… read more here.
Keywords: extend regimen; treatment; type neovascularization; treat extend ... See more keywords
LONG-TERM MORPHOLOGIC CHANGES IN MACULAR NEOVASCULARIZATION UNDER AFLIBERCEPT TREATMENT WITH A TREAT-AND-EXTEND REGIMEN
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003676
Abstract: This retrospective observational study showed that the area of macular neovascularization increased significantly after 2 years despite aflibercept treatment delivered according to a treat-and-extend regimen. The macular neovascularization area at baseline was negatively correlated with… read more here.
Keywords: extend regimen; treatment; macular neovascularization; treat extend ... See more keywords
Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15010059
Abstract: The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a… read more here.
Keywords: macular oedema; regimen ranibizumab; extend regimen; oedema secondary ... See more keywords